Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
European Journal of Neurology2020Vol. 27(8), pp. 1374–1381
Citations Over TimeTop 10% of 2020 papers
Thomas H. Brannagan, A. K. Wang, Teresa Coelho, Márcia Waddington‐Cruz, Michael Polydefkis, P. James B. Dyck, Violaine Planté‐Bordeneuve, John L. Berk, Fábio Barroso, Giampaolo Merlini, Isabel Conceição, Stephen G. Hughes, Jesse Kwoh, Shiangtung W. Jung, Spencer Guthrie, M. Pollock, M. D. Benson, Morie A. Gertz, for the NEURO‐TTR open‐label extension investigators
Abstract
Inotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long-term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed.
Related Papers
- → Spinal multifocal amyloidosis derived from wild-type transthyretin(2011)25 cited
- → Transthyretin amyloidosis: a little history of hereditary amyloidosis(2017)7 cited
- → New Medications in the Treatment of Hereditary Transthyretin Amyloidosis(2018)4 cited
- → Systemic transtiretin amyloidosis in the elderly patient with recurrent pleural effusions(2021)1 cited
- → Structurally abnormal transthyretin causing familial amyloidotic polyneuropathy in Sweden(1987)28 cited